An open-source automated genomic reanalysis tool called Talos showed strong rare-disease diagnostic yield in a study published in Nature Medicine. Researchers tested Talos on the genomes of 4,735 patients with unsolved rare conditions, reporting 241 diagnoses, with more than half tied to new gene-variant disease associations identified since initial sequencing analyses. Developed by Australia’s Centre for Population Genomics in collaboration with Australian Genomics, the Broad Institute and Microsoft Research, Talos is designed to scale reanalysis that traditionally happens on a case-by-case basis. The team emphasized redeployability, allowing institutions to customize sensitivity and specificity settings for clinical use. The results underscore how scientific databases and variant interpretation updates can be operationalized for patients who remain undiagnosed, while maintaining the clinical requirement for manual review to control false-positive risk.